Basecamp Research has raised $140 million in a Series C funding round to advance its AI-designed drug pipeline. The round was led by S32 Ventures and included participation from NVIDIA and Anthropic.
TL;DR
- Basecamp Research secures $140 million in Series C funding to advance AI-designed therapies.
- The company's EDEN model, trained on the Trillion Gene Atlas, aims to revolutionize drug development with a focus on in vivo cell therapies.
- This funding round underscores the growing trend of AI investment in biotech, with notable participation from tech giants like NVIDIA and Anthropic.
What happened
Basecamp Research, a London- and Boston-based biotech company, has closed a $140 million Series C funding round. The round was led by S32 Ventures and included contributions from NVIDIA, Anthropic, and senior leaders from biopharma, including Roche Vice Chairman André Hoffmann.
The funding will be used to advance Basecamp's investigational medicines produced through EDEN, with an initial focus on in vivo cell therapies. These therapies aim to rewire a patient's cells from inside the body, making cell therapies more customizable and easier to deliver.
Why it matters
This funding round highlights the increasing interest and investment in AI-driven biotech startups. The participation of NVIDIA and Anthropic underscores the strategic importance of AI in drug development.
Basecamp's EDEN model, trained on the Trillion Gene Atlas, represents a significant advancement in AI-designed therapies. The model's ability to generate potential drug candidates, such as peptides, enzymes, and cell and gene therapies, could revolutionize the biotech industry.
For developers and investors, this news signifies the growing trend of AI investment in biotech. The success of Basecamp's funding round could pave the way for more AI-centric drugmakers, attracting further investment and innovation in the field.
Key facts
- Basecamp Research raised $140 million in a Series C funding round.
- The round was led by S32 Ventures and included participation from NVIDIA and Anthropic.
- Basecamp's EDEN model is trained on the Trillion Gene Atlas, the largest biological dataset for training AI models.
- The funding will advance investigational medicines with a focus on in vivo cell therapies.
- Roche Vice Chairman André Hoffmann contributed to the funding round.
- Basecamp aims to make cell therapies more customizable and easier to deliver.
- The biotech industry is seeing a surge in AI investment, with notable rounds from companies like Isomorphic Labs and Enveda.
Context
The biotech industry is undergoing a transformation driven by AI. Companies like Basecamp Research are at the forefront of this change, using machine learning models to design and develop new therapies.
The participation of tech giants like NVIDIA and Anthropic in Basecamp's funding round highlights the strategic importance of AI in drug development. These companies are investing in AI-centric biotech startups to drive innovation and advance the field.
The growing trend of AI investment in biotech is attracting more generalist investors. The success of companies like Basecamp Research could pave the way for more AI-centric drugmakers, further revolutionizing the biotech industry.
